BioNTech SE (BNTX) stock

BNTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 10, 2026Score 3/30

$85.60+0.56 (+0.66%)

Close on Nov 13, 2026Market cap $21.50BP/E –Yield –

BioNTech r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was €2.10B, down 6.6% from the year before. The highest annual figure on record is €2.25B in fiscal 2024.

Annual r&d expenses

Period	Period end	Value	Change
FY2025	Dec 31, 2025	€2.10B	-6.6%
FY2024	Dec 31, 2024	€2.25B	+26.4%
FY2023	Dec 31, 2023	€1.78B	+16.0%
FY2022	Dec 31, 2022	€1.54B	+61.9%
FY2021	Dec 31, 2021	€949.20M	+47.2%
FY2020	Dec 31, 2020	€645.00M	+184.8%
FY2019	Dec 31, 2019	€226.50M	+58.3%
FY2018	Dec 31, 2018	€143.04M	+67.3%
FY2017	Dec 31, 2017	€85.50M	–

Where these numbers come from

Parsed from the XBRL in BioNTech's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BNTX.

Compare: BNTX vs MRNA · BNTX vs QGEN · BNTX vs EXEL · BNTX vs HALO · BNTX vs ALVO

Revenue growth4.3% · median 13.1%

Gross margin77.6% · median 82.3%

Operating margin-49.0% · median 37.4%

Net margin-39.6% · median 26.9%

Company	Revenue	Growth
BNTX	€2.87B	+4.3%
MRNA	$2.53B	+13.1%
EXEL	$2.50B	+9.1%
HALO	$1.80B	+45.0%
QGEN	–	–
ALVO	–	–

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 500
Held by institutions: 18.9%
Auditor: EY GmbH & Co. KG Wirtschaftsprufungsgesellschaft
SEC CIK: 1776985

Advertisement
300 × 250

See a number that looks wrong?